Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization

被引:1
|
作者
Fan, Mi [1 ,2 ]
Niu, Tingting [1 ,2 ]
Lin, Binwei [1 ]
Gao, Feng [1 ]
Tan, Bangxian [2 ]
Du, Xiaobo [1 ,2 ,3 ]
机构
[1] Univ Elect Sci & Technol, Mianyang Cent Hosp, Sch Med, Dept Oncol,NHC Key Lab Nucl Technol Med Transforma, Mianyang 621000, Sichuan, Peoples R China
[2] North Sichuan Med Coll, Dept Oncol, Affiliated Hosp, Nanchong 637000, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol, Mianyang Cent Hosp, Sch Med, Dept Oncol,NHC Key Lab Nucl Technol Med Transforma, 12 Changjiaxiang Rd, Mianyang 621000, Sichuan, Peoples R China
关键词
hepatocellular carcinoma; serum ferritin; transarterial chemoembolization; biomarker; prognosis; LIVER-CANCER; TACE;
D O I
10.3892/mco.2024.2720
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study investigated the prognostic impact of preoperative serum ferritin (SF) levels on the survival of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Clinicopathological characteristics and laboratory biomarkers of 223 patients with HCC who underwent TACE were retrospectively reviewed. The Kaplan-Meier method was used to calculate the overall survival (OS), and the log-rank test was used to evaluate statistical significance. Univariate and multivariate analyses were performed using Cox proportional hazards regression to evaluate the prognostic impact of SF in these patients. The present findings identified extrahepatic metastases [hazard ratio (HR)=0.490,95%; confidence interval (CI)=0.282-0.843; P=0.010)] and vascular invasion (HR=0.373; 95% CI=0.225-0.619; P<0.0001) as independent prognostic factors for OS. However, preoperative SF levels could not independently predict OS when compared with other prognostic factors (HR=0.810; 95% CI=0.539-1.216; P=0.309). In conclusion, preoperative SF level is an unreliable biochemical predictor of survival in patients with HCC undergoing TACE.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Transarterial chemoembolization for patients with hepatocellular carcinoma
    Forner, Alejandro
    Real, M. Isabel
    Varela, Maria
    Bruix, Jordi
    HEPATOLOGY RESEARCH, 2007, 37 : S230 - S237
  • [32] Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization
    Hsu, Chia-Yang
    Huang, Yi-Hsiang
    Su, Chien-Wei
    Lin, Han-Chieh
    Chiang, Jen-Huey
    Lee, Pui-Ching
    Lee, Fa-Yauh
    Huo, Teh-Ia
    Lee, Shou-Dong
    LIVER INTERNATIONAL, 2010, 30 (01) : 77 - 84
  • [33] Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Ventura, Yossi
    Carr, Brian I.
    Kori, Issac
    Guerra, Vito
    Shibolet, Oren
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (15) : 1641 - 1649
  • [34] Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Tez, Mesut
    Zulfikaroglu, Baris
    CANCER, 2008, 112 (12) : 2820 - 2821
  • [35] Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Sohn, Won
    Ham, Cheol Bae
    Kim, Nam Hee
    Kim, Hong Joo
    Cho, Yong Kyun
    Jeon, Woo Kyu
    Kim, Byung Ik
    PLOS ONE, 2020, 15 (12):
  • [36] Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Cho, Yun Ku
    Chung, Jin Wook
    Kim, Jae Kyun
    Ahn, Yong Sik
    Kim, Mi Young
    Park, Yoon Ok
    Kim, Wan Tae
    Byun, Jong Hoon
    CANCER, 2008, 112 (02) : 352 - 361
  • [37] Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization
    Gan, Delu
    Wang, Yali
    Yang, Xin
    Huang, Juan
    Zhang, Lijun
    Guo, Bianqin
    Li, Pu
    Gou, Dan
    LABORATORY MEDICINE, 2025,
  • [38] Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: An Australian multicenter cohort study
    Mishra, G.
    Dev, A.
    Paul, E.
    Roberts, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 93 - 94
  • [39] Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization
    Sangheun Lee
    Jung Hyun Kang
    Do Young Kim
    Sang Hoon Ahn
    Jun Yong Park
    Beom Kyung Kim
    Seung Up Kim
    Kwang-Hyub Han
    Hepatology International, 2017, 11 : 292 - 299
  • [40] Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization
    Lee, Sangheun
    Kang, Jung Hyun
    Kim, Do Young
    Ahn, Sang Hoon
    Park, Jun Yong
    Kim, Beom Kyung
    Kim, Seung Up
    Han, Kwang-Hyub
    HEPATOLOGY INTERNATIONAL, 2017, 11 (03) : 292 - 299